Evidence map›Paper›PMID 40663406›Full record

ArticleJCI insight2025

Prophylactic and therapeutic neutralizing monoclonal antibody treatment prevents lethal yellow fever infection.

Lauren N Rust, Michael J Ricciardi, Savannah S Lutz, Sofiya Yusova, Johan J Louw, Aaron Yrizarry-Medina, Sreya Biswas, Miranda Fischer, Aaron Barber-Axthelm, Gavin Zilverberg and 22 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCI insight, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Lauren N RustOregon National Primate Research Center (ONPRC), Oregon Health and Science University, Beaverton, Oregon, USA.
Michael J RicciardiMabloc LLC, Washington DC, USA.
Savannah S LutzOregon National Primate Research Center (ONPRC), Oregon Health and Science University, Beaverton, Oregon, USA.
Sofiya YusovaOregon National Primate Research Center (ONPRC), Oregon Health and Science University, Beaverton, Oregon, USA.
Johan J LouwGeorge Washington University, Washington DC, USA.
Aaron Yrizarry-MedinaGeorge Washington University, Washington DC, USA.
Sreya BiswasOregon National Primate Research Center (ONPRC), Oregon Health and Science University, Beaverton, Oregon, USA.
Miranda FischerVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, USA.
Aaron Barber-AxthelmOregon National Primate Research Center (ONPRC), Oregon Health and Science University, Beaverton, Oregon, USA.
Gavin ZilverbergOregon National Primate Research Center (ONPRC), Oregon Health and Science University, Beaverton, Oregon, USA.
Lauren BaileyOregon National Primate Research Center (ONPRC), Oregon Health and Science University, Beaverton, Oregon, USA.
Tonya SwansonOregon National Primate Research Center (ONPRC), Oregon Health and Science University, Beaverton, Oregon, USA.
Rachael TonelliOregon National Primate Research Center (ONPRC), Oregon Health and Science University, Beaverton, Oregon, USA.
G W McElfreshOregon National Primate Research Center (ONPRC), Oregon Health and Science University, Beaverton, Oregon, USA.
Brandon C RosenGeorge Washington University, Washington DC, USA.
Thomas B VoigtGeorge Washington University, Washington DC, USA.
Christakis PanayiotouGeorge Washington University, Washington DC, USA.
Jack T MauterGeorge Washington University, Washington DC, USA.
Noor GhoshGeorge Washington University, Washington DC, USA.
Jenna MeanorGeorge Washington University, Washington DC, USA.
Giovana GodoyGeorge Washington University, Washington DC, USA.
Michael AxthelmOregon National Primate Research Center (ONPRC), Oregon Health and Science University, Beaverton, Oregon, USA.
Jeremy SmedleyOregon National Primate Research Center (ONPRC), Oregon Health and Science University, Beaverton, Oregon, USA.
Mark K SlifkaOregon National Primate Research Center (ONPRC), Oregon Health and Science University, Beaverton, Oregon, USA.
Esper G KallasDepartment of Infectious Diseases and Tropical Medicine, School of Medicine, University of São Paulo, São Paulo, Brazil.
Gabriela WebbOregon National Primate Research Center (ONPRC), Oregon Health and Science University, Beaverton, Oregon, USA.
Robert ZweigOregon National Primate Research Center (ONPRC), Oregon Health and Science University, Beaverton, Oregon, USA.
Caralyn S LabriolaVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, USA.
Benjamin N BimberOregon National Primate Research Center (ONPRC), Oregon Health and Science University, Beaverton, Oregon, USA.
Jonah B SachaOregon National Primate Research Center (ONPRC), Oregon Health and Science University, Beaverton, Oregon, USA.
David I WatkinsMabloc LLC, Washington DC, USA.
Benjamin J BurwitzOregon National Primate Research Center (ONPRC), Oregon Health and Science University, Beaverton, Oregon, USA.

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
Learning from the Ebola success: Can a mAb also save lives after yellow fever infection?R42AI155275 · NIAID · MABLOC, LLC · PI WATKINS, DAVID I · 2020 to 2023
$3.3M
NIAID NIH HHS R42 AI155275NIH HHS P51 OD011092
6 · The paper itself

Abstract

Yellow fever virus (YFV) infection is fatal in 5%-10% of the 200,000 yearly cases. There is currently no available antiviral treatment. We showed previously that administration of 50 mg/kg of a YFV-specific neutralizing monoclonal antibody (nmAb) at 2 days postinfection (dpi), prior to the onset of severe disease, protected YFV-infected rhesus macaques from death. To further explore the clinical applicability of our nmAb MBL-YFV-01, we treated rhesus macaques with a lower dose (10 mg/kg) of this nmAb prophylactically or therapeutically at 3.5 dpi. We show that a single prophylactic or therapeutic i.v. dose of our nmAb protects rhesus macaques from death following challenge. A comprehensive analysis of 167 inflammatory cytokine and chemokines revealed that protection was associated with significantly reduced expression of 125 of these markers, including type I IFN, IL-6, and CCL2. This study further expands the potential clinical use of our YFV-specific nmAb, which could be used during an outbreak for immediate prophylactic immunity or for patients with measurable serum viremia.

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralYellow FeverYellow fever virusAnimalsCytokinesDisease Models, AnimalFemaleHumansMacaca mulattaMaleAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCytokinesHepatitisImmunologyInfectious diseaseTherapeutics

Identifiers

PMID40663406
PMCPMC12416903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.